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Abstract Developmental insults during gestation, such as
under-nutrition, are known to restrict the number of beta cells
that form in the fetal pancreas and are maintained in adulthood,
leading to increased risk of type 2 diabetes. There are now
substantial data indicating that glucocorticoids mediate this
effect of under-nutrition on beta cell mass and that even at
physiological levels they restrain fetal beta cell development in
utero. There are emerging clues that this occurs downstream of
endocrine commitment by neurogenin 3 but prior to terminal
beta cell differentiation. Deciphering the precise mechanism
will be important as it might unveil new pathways by which to
manipulate beta cell mass that could be exploited as novel
therapies for patients with diabetes.
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The last 20 years have seen marked interest in the
hypothesis that environmental insults to the fetus can
programme future cardiovascular and metabolic disorders
in the offspring [1, 2]. The ‘fetal origins of adult disease’
hypothesis was borne of epidemiological data associating
gestational under-nutrition and low birthweight with future
conditions, including type 2 diabetes. As adult euglycaemia
is dependent on gaining an adequate number of insulin-
secreting beta cells (‘beta cell mass’) as well as their
subsequent maintenance, mechanistic studies have since
queried how such insults might compromise beta cell
development within the fetal pancreas [3].
Major understanding of beta cell specification has arisen
from studying signalling pathways and nuclear transcription
factors, largely in rodents, that regulate the sequential
commitment of multipotent progenitors down different
pancreatic lineages to terminal differentiation [4, 5].
Variation in the balance of activity of these pathways and
transcription factors within defined developmental window
periods alters beta cell specification relative to other
pancreatic cell types. However, superimposed on this
specification ‘blueprint’, it is also possible to conceptualise
a more subtle rheostatic control from nutrients or hormones
to amplify or restrain the numbers of cells appropriately
differentiating to a particular fate.
In this issue of Diabetologia, further evidence is
provided from Bréant, Blondeau and colleagues for the
important role of glucocorticoids (GCs) as critical hor-
mones mediating the effect of under-nutrition on reducing
beta cell mass [6]. Work by the same authors and others has
previously linked maternal under-nutrition in rats with
raised fetal levels of corticosterone (the main GC in
rodents, comparable with cortisol in human) to an estimated
halving of beta cells in the pancreas [7, 8]. Maternal
adrenalectomy and baseline corticosterone replacement
almost entirely abrogated this effect, implying the causal
link with adrenocortical hormones [7]. Here, in corrobora-
tion, inactivating the glucocorticoid receptor (GR) in the
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developing mouse pancreas blocked the reduction in beta
cell mass caused by under-nutrition [6]. Indeed during
normal gestation, loss of GR led to a significant increase in
beta cells [6, 8]. The combined data demonstrate several
key points. There is a central role for GC–GR signalling in
restraining beta cell mass, and this occurs physiologically
not just pathologically. Whereas restored or increased beta
cell mass came from causing GR inactivation by Pdx1
expression (an early event in pancreas development), that
controlled by insulin expression (a late, beta cell specific
event) had no effect. The regulatory sequences from both
genes are widely used in mice to induce Cre recombinase
production and are well validated [9, 10]. Although,
theoretically, GR inactivation at duodenal sites of Pdx1
expression might be responsible, the more likely interpre-
tation is that GC–GR action is influential after the
specification of Pdx1-positive pancreatic progenitor cells
but prior to terminal beta cell differentiation.
In addition to reducing beta cell development, GCs
increased gene expression associated with exocrine devel-
opment. Transcripts of the pro-exocrine transcription factor,
Ptf1a, amylase and carboxypeptidase A were all approxi-
mately doubled while those for the endocrine commitment
transcription factor, Neurogenin 3 (Ngn3), and later
markers of beta cell differentiation were slightly reduced
[6]. Similarly, dexamethasone, a potent synthetic GC,
increased exocrine tissue in rat explants in vitro [8]. This
suggests that gestational under-nutrition via GC–GR sig-
nalling might switch multipotent pancreatic progenitors to
an exocrine fate at the expense of endocrine cells.
Dexamethasone can cause transdifferentiation between cell
types [11]. Inducing endocrine–exocrine perturbation is
possible during mouse pancreas development prior to
embryonic day (E) 14, by which stage exocrine specification
from multipotent progenitors is largely complete [12, 13].
However, timing is everything and several lines of evidence
suggest that the critical window period for under-nutrition
and the effect of GCs is later in pancreas development.
Compromised beta cell function in rat is observed
following maternal dexamethasone treatment in the final
week of gestation but not at earlier stages [14]. In the
mouse, pancreatic GR production rises between E14.5 and
E16.5, peaks at E16.5 and has fallen sharply by E17.5 [15].
Following GR inactivation, mouse pancreas appeared
normal at E15.5 during major endocrine commitment due
to transient Ngn3 production [16, 17]. Taken together, these
data imply that GC restriction of beta cell development
occurs perhaps coincident with, but more likely after, Ngn3
production and prior to that of insulin. This interpretation of
a relatively late effect of GCs on endocrine differentiation
would also dictate that the exocrine observations are either
secondary or in parallel rather than part of an endocrine–
exocrine phenotypic switch mechanism.
It seems feasible that the major role of GR signalling is
to restrain cell proliferation at later stages of beta cell
differentiation. Following Pdx1-regulated GR inactivation
the authors in this issue report increased BrdU incorpora-
tion as a marker of recent proliferation in insulin-positive
cells as well as in nearby insulin-negative cells (Fig. 6d in
[6]). Further immunohistochemistry would be useful to
identify these insulin-negative BrdU-positive cells by co-
localisation with transcription factors produced after Ngn3,
such as neurogenic differentiation 1 (Neuro1), paired box
gene 6 (Pax6), ISL1 transcription factor, LIM/homeodo-
main (Isl1), NK2 transcription factor related, locus 2
(Drosophila, Nkx2.2), NK6 homeobox 1 (Nkx6.1) and v-
maf musculoaponeurotic fibrosarcoma oncogene family,
protein A (avian) (MafA), as well as other endocrine
hormone markers. Potential involvement of the MODY 1
gene, HNF4α is intriguing. Dexamethasone causes a switch
in use from the P2 to the P1 promoter of Hnf4α and
increases transcript levels in the liver [18]. Both promoters
are active in the human fetal pancreas making HNF4α
expression potentially sensitive to GCs during beta cell
development [19]. Inactivating mutations in HNF4a that
later give rise to diabetes paradoxically present with
hyperinsulinaemia and macrosomia at birth [20]; cellular
levels of other genes in the insulin secretion pathway are
unchanged, implying that loss of HNF4α increases the
number of fetal beta cells. Piecing these datasets together,
GCs could act during beta cell development to increase
functional HNF4α which, despite being required in
postnatal beta cells, seems unexpectedly to restrain fetal
beta cell mass. Accurately identifying the genetic targets of
GR action will be complex: the function of the nuclear
hormone receptor varies widely according to the setting and
includes both activation and repression [21]; as well as
directly regulating transcription, GR binding to DNA can
profoundly modify chromatin structure, affecting potential
access to adjacent DNA for a range of other transcription
factors; it can influence transcriptional activity of other
factors via protein–protein interaction off DNA [21]; and
genetic targets vary according to whether GC delivery is
pulsatile or continuous [22, 23].
For relevance in diabetes it will be important to translate
these findings from rodent models. In considering potential
programming of human fetuses by GCs, a lot of attention
has focussed on placental transfer of maternal cortisol during
the third trimester of gestation and the adequacy or otherwise
of the placental enzyme type 2 11β-hydroxysteroid dehydro-
genase (HSD11B2), which inactivates cortisol to cortisone
[14, 24]. Although late gestation is the period that most
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profoundly influences birthweight, this phase and maternal
transfer may not be the most important factors for GC
programming of beta cell mass. Timed with the first wave of
beta cell differentiation and islet formation [25, 26], the
presence of NGN3 protein has been most consistently
reported late in the first trimester and early in the second
trimester of human gestation [27–29]. Reports of the
transcription factor later in pregnancy are conflicting, with
some groups unable to detect it [30]. During this period of
8–14 weeks post-conception, transfer of maternal cortisol
across the placenta seems of secondary importance to fetal
adrenocortical production; female fetuses with congenital
adrenal hyperplasia due to 21-hydroxylase deficiency would
otherwise not be so profoundly cortisol-deficient as to
virilise [31, 32]. In contrast, the first trimester human fetal
adrenal is remarkable for its cortisol secretion, with GC
action via GR in the anterior pituitary able to regulate ACTH
secretion [33]. This raises the possibility that factors even
subtly varying human fetal cortisol production, such as
polymorphic variations in key enzymes, may influence
pancreatic beta cell development. Concordant with these
combined speculations, data from people born during or
soon after the Dutch winter famine of 1944–1945 have
demonstrated that impaired glucose tolerance in later life
with seemingly deficient insulin secretion correlated most
strongly with food restriction during their early and mid-
gestation, but not the last trimester [34].
In summary, there has been clear progress in resolving the
mechanistic complexity of gestational under-nutrition on beta
cell development down to a role for a single hormone, now
robustly corroborated by genetic inactivation of its nuclear
hormone receptor [6]. Alongside the value of understanding
such risk factors for type 2 diabetes, discovering hormones
and other secreted factors that regulate beta cell development
may offer clues for new drug development to enhance beta
cell mass. In the case of GR, novel ligands are an area of
intense pharmaceutical activity [35, 36]. Further mechanistic
understanding of GR action may even throw up new
pathways for potential manipulation. However, regardless of
such possibilities, as molecular research has tended to focus
us ever deeper into the nucleus, it is perhaps comforting—as
diabetologists and endocrinologists—that ‘old-fashioned’
hormone communication between our favourite organs
remains important during gestation as well as postnatally.
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